<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055965</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000271903</org_study_id>
    <secondary_id>CHNT-GEM-HOSP</secondary_id>
    <secondary_id>EU-20245</secondary_id>
    <nct_id>NCT00055965</nct_id>
  </id_info>
  <brief_title>Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin</brief_title>
  <official_title>A Pragmatic, Randomised Study To Compare The Hospitalisation Rates Of Two Platinum-Based Outpatient Regimens (Gemcitabine/Cisplatin vs. Gemcitabine/Carboplatin) In Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known if one regimen will require patients to spend more time in the hospital than the&#xD;
      other regimen for treatment of chemotherapy-related side effects.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the hospitalization rates of patients who are&#xD;
      receiving gemcitabine combined with cisplatin with that of patients receiving gemcitabine&#xD;
      combined with carboplatin for unresectable stage III or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the rates of overnight hospitalization due to toxicity (e.g., blood transfusion,&#xD;
           antibiotic use, and to obtain relief of treatment-related symptoms) of patients with&#xD;
           non-small cell lung cancer treated with gemcitabine and cisplatin vs gemcitabine and&#xD;
           carboplatin.&#xD;
&#xD;
        -  Compare the need for hospitalization for chemotherapy administration in patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Compare the tumor response rate of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the relief of tumor-related symptoms in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the effect on Karnofsky performance status in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the toxic effects of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to stage&#xD;
      (IIIA vs IIIB [dry] vs IIIB [wet] or IV) and performance status (50-60% vs 70-100%). Patients&#xD;
      are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1-2 hours&#xD;
           on days 1 and 8.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin&#xD;
           IV over 30-60 minutes on day 1.&#xD;
&#xD;
      In both arms, treatment repeats every 21 days for up to 4 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 2 months for 6 months and then every 3-4 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 400 patients (200 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2002</start_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of hospitalization due to toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for hospitalization for chemotherapy administration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief of tumor-related symptoms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Karnofsky performance status</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by NCIC CTC v2.0</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed inoperable non-small cell lung cancer&#xD;
&#xD;
               -  Stage IIIA, IIIB, or IV&#xD;
&#xD;
               -  Not eligible for curative radiotherapy or surgery&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 3 times ULN (5 times ULN if liver metastases&#xD;
             present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             completion&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No serious systemic disorder that would preclude study participation&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No significant neurological problems (e.g., seizures or psychiatric disorders)&#xD;
&#xD;
          -  No other active malignancy within the past 5 years except carcinoma in situ of the&#xD;
             cervix or adequately treated non-melanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy during or for 7 days after study therapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy during or for 7 days after study therapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 12 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent antitumor therapy&#xD;
&#xD;
          -  No concurrent experimental medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Thatcher, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

